April 10, 2025 NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC’s Promise as a Disease-Modifying ALS Treatment Read More
December 24, 2024 NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS Read More
December 11, 2024 NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Read More
December 2, 2024 NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price Read More
October 24, 2024 New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Read More
October 15, 2024 NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates Read More
October 7, 2024 NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting Read More
September 24, 2024 NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer’s Read More
August 7, 2024 NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price Read More
July 9, 2024 NeuroSense’s PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression Read More
July 1, 2024 NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS Read More
May 14, 2024 NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning Read More
April 18, 2024 NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting Read More
December 14, 2023 NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial Read More
December 5, 2023 NeuroSense’s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints Read More
November 6, 2023 NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 Read More
October 4, 2023 NeuroSense’s PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model Read More
September 19, 2023 NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC Read More